Since the Oxford Classification of IgA nephropathy (IgAN) 
In this report we review the relevant studies published since 2009, as well as reporting the published and yet unpublished studies of our working subgroups. We make recommendations for changes to the Oxford Classification, and also propose further work which will improve still further the value of the classification in research and in clinical practice.
Published retrospective validation studies
A limitation of the original Oxford study cohort was that it included only 265 adults and children, and only those of White Caucasian (from Europe and North America) and East
Asian (from China and Japan) ethnicities. Furthermore, the cohort was selected to be enriched for typical slowly progressive IgAN, excluding patients with very low levels of proteinuria. It also excluded those with estimated GFR <30ml/min with the intent of avoiding the selection of very advanced cases in which glomerulosclerosis and interstitial fibrosis would be dominant, but having the effect of also excluding some rapidly progressive cases in which crescents might more likely be predictive of outcome.
Since 2009, numerous studies have been published which apply the Oxford classification to cohorts of subjects with IgAN. These studies are typically described as validation studies, although none prospectively studied new cohorts; nevertheless they provide valuable corroborative evidence. Sixteen such studies [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , including cohorts from Europe, North America, and East Asia were meta-analysed in a report published in 2013 21 . Lately, more studies have been published including cohorts from Iran, Europe, Japan and Korea [22] [23] [24] [25] [26] [27] [28] . All these studies are summarised in Supplementary Table 1 .
Review of current classification parameters (M, E, S, and T)
The published cohorts provide robust and consistent evidence that M, S and T lesions each reliably provide prognostic information by univariate analysis, although only T lesions were a consistent, independent predictor of renal outcomes, with more variable results for M and S (Table 1) . This is likely to be a consequence of the endpoint (end stage renal disease, ESRD) chosen in most studies. T score largely reflects the stage of disease at the time of biopsy; those patients with more advanced chronic damage have a shorter time to ESRD. Those studies that included rate of loss of renal function as an endpoint, more consistently reported that active, cellular lesions (M and E score) were associated with this outcome.
E (endocapillary hypercellularity)
The E lesion was not predictive of outcomes in the original Oxford Classification cohort, and this was also true in most of the subsequent studies (Table 1) . However, the original
Oxford Classification cohort and all but two of the published validation studies show treatment bias, with non-random immunosuppression. Patients whose biopsies were scored E1 were more likely to receive immunosuppressive therapy, most frequently corticosteroids, and patients with E lesions had an improved outcome if treated with corticosteroids. The two studies in which no patients received corticosteroid/cytotoxic therapy both reported that E1 was independently associated with more rapid loss of renal function and worse renal survival 8, 27 . This is consistent with the reversibility of E following immunosuppression in a study reporting repeat renal biopsies after treatment 29 . These studies suggest that the use of immunosuppression may mask the predictive value of E on renal outcomes. While these findings do not in themselves support the routine use of immunosuppression when the E lesion is present, they do justify a prospective trial of immunosuppression in IgAN with the E lesion. 30 . This showed that podocyte hypertrophy or sclerosis at the tubular pole (tip lesion), features typically associated with podocytopathies, were associated with more proteinuria at presentation and a more rapid decline in renal function. In addition, in individuals with podocyte hypertrophy or tip lesions, immunosuppressive therapy was associated with a better renal survival. The identification of these podocytopathic features was found to be reproducible between the pathologists in the study but it remains to be determined whether this is also the case for pathologists in different units around the world. If the associations between histological subclassification of segmental sclerosis and outcome are confirmed, then a refinement of the definition of the S lesion may be appropriate, using S1 only for sclerotic lesions with podocytopathic features. Pending such studies we recommend no change in the definition of S1, but reporting all S1 lesions with additional descriptive text "segmental sclerosis with/without podocyte hypertrophy/tip lesions".
S (Segmental sclerosis)

Additional pathological features considered for inclusion in the Oxford Classification
Pattern of glomerular IgA deposition
The Oxford Classification was developed using light microscopic findings only. Other reports have suggested that the presence of IgG, in addition to IgA, and also the location of IgA are predictive of outcome, for example that glomerular capillary wall deposits may carry a worse prognosis than mesangial deposits alone 4 . However, review of the Oxford Classification cohort has shown that whilst the presence of glomerular IgG and capillary wall IgA deposits (identified by immunofluorescence or immunohistochemistry) are associated with a worse outcome, they do not add predictive value to MEST scores 4 .
Crescents
In the original Oxford study 1 and several validation studies with similarly restrictive entry criteria 7,9,15,16 , crescents were not found to be an independent predictor of renal outcomes.
However individuals with severe renal impairment (estimated glomerular filtration rate (eGFR) <30 ml/min) were not included in these studies, and Katafuchi et al found crescents
to be predictive of end stage renal disease in 286 IgAN patients not meeting entry criteria for the original Oxford study 6 . Crescents were also found to be predictive of poor renal outcomes in several other studies including patients with eGFR <30 ml/min 12, 13 31 . Therefore, we propose that the Oxford classification should now involve five components, MEST-C rather than MEST.
Cases of Henoch-Schönlein purpura nephritis were not included in this cohort, so it is not yet possible to confirm whether crescents have similar significance in that condition.
Quantification of glomerular macrophages
It has been proposed that E1 in IgAN is a reflection of glomerular inflammation and that use of immunohistochemistry for CD68 to identify glomerular macrophages might assist in the recognition of E1 lesions, and be potentially superior to evaluation of PAS-stained sections in prognostication. There is provisional data from the study of biopsies in a cohort which received no immunosuppression, and in which E1 was an independent predictor of rate of loss of renal function and renal survival 27 . In these biopsies quantitative analysis of CD68-stained sections has demonstrated that the number of glomerular macrophages correlates strongly with extent of endocapillary hypercellularity and E1 score, assessed on PAS-stained sections, but not M, S or T scores. Using a cut-off of a maximum glomerular macrophage count of 6 correctly identifies E score in 80% of biopsies 32 . It remains to be determined whether glomerular macrophage counts have superior clinical value to E scoring.
Children
The validation studies in children <18 years old from Japan 13 33 . In other cohorts, significant predictive values for some scores (mostly M, E and T) were found in models including clinical data at renal biopsy. The most powerful predictive factor in children and young subjects, using Cox models as well as tree analysis, is M1. In the Japanese cohort the presence of crescents in >30% glomeruli was also significant in multivariate models considering proteinuria at biopsy 13 . These analyses stress the need for a collaborative effort to generate a large database for children with IgAN in order to solve the problem of inadequate statistical power due to small numbers of progressive cases especially with relatively short periods of follow-up.
Combined clinicopathological information
The major aims of our work in developing and refining a classification of IgAN are to improve the prognostic information for individual patients and recruitment criteria into clinical trials. Earlier prediction algorithms sought to integrate clinical findings at presentation and over time with renal pathology using the histological classifications for IgAN available at the time 34 . By univariate analysis many clinical and pathological elements were relevant to outcomes but by multivariate analysis the only factors which maintained their independent value were mean arterial pressure and urine protein excretion over time 34 .
Maximum predictive power to explain variabilities in outcome in any patient, was only available when mean arterial pressure and proteinuria were followed for a two-year period.
Recently, this was explored further using a combined cohort of 901 adults from the original Oxford cohort, the North American validation study and the VALIGA study. The previous prediction algorithm, using clinical data (including proteinuria, mean arterial function and glomerular filtration rate) over the first 2 years was repeated using the hard endpoints of a Other prediction models for outcome in IgAN have been published 35 using a variety of pathological features and clinical features. Our working group will continue to refine these prediction models using the MEST-C score and will seek international consensus so that one prediction model enters common usage. This will not only benefit individual patient care but will also facilitate collaborative research, and enable comparison and interpretation of different studies.
The Revised MEST-C Score
Criteria for adequacy of renal biopsy, for scoring of M, E, and T lesions, and for overall reporting of IgAN biopsies are unchanged from our original recommendations 1,2 (Boxes 1 & 2). In light of the recent data summarised above, we recommend the addition of a C (crescent score) to MEST. All adequate biopsies with a diagnosis of IgAN should be scored as C0 (no crescents), C1 (crescents in a least one but <25% of glomeruli or C2 (crescents in at least 25% of glomeruli) (Boxes 1 & 2). We also recommend refining the S score, noting the presence or absence of podocytopathic features (podocyte hypertrophy/tip lesions) in biopsies scored as S1.
Therefore, we propose that the renal biopsy in IgAN should be reported using a fivecomponent MEST-C score. Since cases of Henoch-Schönlein purpura nephritis were excluded from the recent study of crescents in IgAN 31 , we recommend the MEST-C score not to be applied to cases of Henoch-Schönlein purpura nephritis yet.
Reproducible identification of MEST: need for an educational tool
The definitions for each component in the Oxford Classification were the result of an iterative process involving the renal pathologists in the original working group 2 . Definitions were written to be straightforward and to maximise the likelihood that pathologists would be able to consistently identify the lesions in clinical practice. However, a subsequent analysis using the VALIGA cohort showed significant inconsistencies in identification of M and E lesions 33 . Local pathologists diagnosed M1 twice as often as the central review pathologist and E1 three times as often. The M score given by the central but not the local pathologists was an independent predictor of renal outcome. To help overcome this issue a web-based tool has been developed to provide examples of each lesion and assist pathologists to overcome the commonly identified reporting errors. The link to training slides will soon be available on the Renal Pathology Society website (www.renalpathsoc.org). Approximately 5000 such patient datasets including children and adults have been collected and preliminary analysis has been published 36 . This cohort will be a powerful substrate for further studies in IgAN to improve outcome prediction for individual patients, and refine recruitment and outcome criteria for clinical trials. The primary purpose will be to validate a prediction model in IgAN applicable worldwide across the range of disease severity and ethnic groups, and easy to use in clinical practice (analogous to the Framingham prediction rule for cardiovascular disease). In addition, we expect this cohort be a data source for further studies including the potential for virtual assessment of novel biomarkers.
Next Steps
Development of international cohorts for further studies
Biomarkers
An important research focus in IgAN is the identification of novel biomarkers which can add to the available information through clinical and pathological features improving diagnosis, risk stratification, therapy selection, prediction of response to therapy, and risk of transplant recurrence. With the continued evolution of "omics" platforms it is now possible to measure a very wide range of potential 'biomarkers' in the serum, plasma, urine, and kidney.
However, in IgAN there are few such biomarker studies and they lack rigorous prospective validation in diverse populations 37 . Variable collection and storage of biological samples for biomarker analysis can be a significant confounder in such analyses. Undergalactosylated serum IgA1 and circulating autoantibodies to that IgA1 have been studied and may add value in predicting progression risk and transplant recurrence 38 . Biomarkers have the potential to improve prediction of end stage renal disease, to assist the clinician in managing individual patients, and to define surrogate end points for the evaluation of clinical trials. To maximize the opportunity being created by the described large international IgAN cohort, recommendations will be agreed and published covering the collection, storage, and transport of biological specimens for biomarker analysis.
Discussion
The active study of the Oxford Classification of IgAN since its original publication has led to the assembly of substantial data to endorse its validity in increasingly large and diverse cohorts of patients. This progress provides further assurance that it was correct to develop the Oxford Classification using a rigorous evidence-based approach, which sets it apart from other, largely opinion-based, classifications currently used in renal pathology.
The Oxford Classification has now become the accepted norm used by the majority of Another approach to improving the accuracy of E lesion reporting is to develop an additional cellular marker for endocapillary hypercellularity. Identification of tissue macrophages by CD68 staining is a promising approach which improved accurate identification of the E1 lesion in one study 39 , but corroboration is needed before recommendation for inclusion in the Oxford Classification.
Recent data have clarified the prognostic significance of the E lesion. E1 is predictive of outcome only in patients who have not received immunosuppression. This strongly suggests the E lesion is responsive to immunosuppression, an interpretation supported by evidence from a re-biopsy study showing resolution of E lesions following immunosuppression 29 .
However, there are very few supporting data for this proposition from randomised clinical trials. Further histological data from controlled trials is required to determine the role of the MEST score and selection of therapy.
It has always been intended that the Oxford Classification would be subject to review and development, not least because of the rather narrow inclusion criteria used to assemble the A significant additional benefit of the development of the Oxford Classification for IgAN has been the building of an international network of investigators willing to work together, to sharing data and biosamples, to deliver collaborative projects not attainable by each investigator working with smaller cohorts. This network has now assembled a cohort of over 5000 subjects with detailed consistently held data on demographics, clinical phenotyping, and outcome, expecting to provide the substrate for future studies including analysis of novel biomarkers. Limited numbers provide a challenge to the study of IgAN in children; this cohort addresses this issue by including over 1000 children.
In summary, we propose an extension of the MEST score in the Oxford Classification of IgAN to become a MEST-C score for use in routine clinical practice and research. In addition to providing the evidence base to endorse this recommendation, the continuing efforts of our group have built a network to facilitate the assembly of a large unique cohort of wellcharacterised subjects with IgAN, providing fertile ground for further collaborative international studies addressing the pathogenesis, epidemiology, and clinical care of IgAN patients.
We recommend that MEST criteria are not yet applied to cases of HenochSchönlein purpura nephritis (IgA vasculitis)
BOX 2:
Recommendations for the renal biopsy report in IgA nephropathy Updated from ref. 1, 2, 33 Detailed description of the features present on 
